Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
28 July 2000Website:
http://www.illumina.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 18 min agoDividend
Analysts recommendations
Institutional Ownership
ILMN Latest News
Illumina (ILMN) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $0.33 per share a year ago.
Illumina (ILMN) is trading down guiding a 3% decline in revenue. George Tsilis believes the company is still notable despite the market's reaction.
Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis Core Illumina GAAP operating margin of 68.6% and non-GAAP operating margin of 22.6% for Q3 2024 Core Illumina GAAP diluted EPS of $4.03 and non-GAAP diluted EPS of $1.14 for Q3 2024 Lowered fiscal year 2024 Core Illumina revenue guidance to decline ~3% from fiscal year 2023; expect Q4 2024 Core Illumina revenue of approximately $1.07 billion Raised fiscal year 2024 Core Illumina non-GAAP operating margin guidance to a range of 21% to 21.5% Raised fiscal year 2024 Core Illumina non-GAAP diluted EPS guidance to a range of $4.05 to $4.15 SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2024. The financial results for YTD 2024 and Q3 2023 and YTD 2023 include the financial results for GRAIL which was spun off on June 24, 2024.
New, groundbreaking technology delivers Illumina's most comprehensive genome yet ; early results from Broad Clinical Labs demonstrate a highly simplified workflow , ultra-long phasing, high-resolution insights into complex genomic variation, and enhanced long-range information Illumina and customers will also showcase new details on complete proteomics solution and latest data on Fluent single-cell technology SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will present updates on several key innovations in whole-genome sequencing, proteomics, and single-cell technology at the American Society of Human Genetics (ASHG) Annual Meeting next week in Denver. The latest details will be presented alongside new data from key opinion leaders in next-generation sequencing (NGS), illustrating the potential impact of Illumina's emerging innovations.
In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing customer activity on NovaSeq X.
SAN DIEGO , Oct. 7, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2024 following the close of market on Monday, November 4, 2024. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
Illumina's stock has rebounded 25% since October 2023, despite underwhelming revenue growth and challenges with the NovaSeq X platform and macro headwinds. The company faces issues with the adoption of NovaSeq X, and increased complexity and costs in data processing. Illumina's scalable business model and high-margin consumable revenues offer significant upside, with potential for substantial margin expansion and EPS improvement by 2027.
GRAIL Inc., spun off from Illumina Inc. in June 2024, faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Despite a strong balance sheet, GRAIL's Q2 2024 operational loss was $1.64 billion, primarily due to non-cash goodwill and intangible impairments. GRAIL's restructuring plan aims to cut costs, focus on Galleri sales, and extend its cash runway to 2028, supported by Illumina's continued involvement.
Big jump after earnings led by a pullback, could be an opportunity here.
MIAMI , Sept. 9, 2024 /PRNewswire/ -- The FDA has granted approval on Illumina's TruSight Oncology Comprehensive Assay, marking a transformative milestone in cancer diagnostics.
What type of business is Illumina?
Illumina, Inc. is a global leader in the field of sequencing (technology for reading genetic code) and array-based solutions for genetic and genomic analysis. This area of activity is relatively new and developing. Illumina, Inc. is the author of next-generation sequencing technologies. Illumina, Inc. was founded in 1998. The company's headquarters is located in San Diego, California. Its products and solutions are designed for use in the fields of life sciences, diagnostics, agriculture, pharmaceuticals, and consumer genomics. Illumina, Inc.'s clients include leading genomics research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.
What sector is Illumina in?
Illumina is in the Healthcare sector
What industry is Illumina in?
Illumina is in the Diagnostics & Research industry
What country is Illumina from?
Illumina is headquartered in United States
When did Illumina go public?
Illumina initial public offering (IPO) was on 28 July 2000
What is Illumina website?
https://www.illumina.com
Is Illumina in the S&P 500?
No, Illumina is not included in the S&P 500 index
Is Illumina in the NASDAQ 100?
Yes, Illumina is included in the NASDAQ 100 index
Is Illumina in the Dow Jones?
No, Illumina is not included in the Dow Jones index
When was Illumina the previous earnings report?
No data
When does Illumina earnings report?
The next expected earnings date for Illumina is 08 November 2024